Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
14th Annual Needham Healthcare Conference (Replay)
04/15/15 at 8:40 a.m. ET
14th Annual Needham Healthcare Conference
Wednesday, April 15, 2015 8:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
40th Annual Deutsche Bank Health Care Conference  (Live)
05/07/15 at 12:50 p.m. ET
40th Annual Deutsche Bank Health Care Conference
Thursday, May 7, 2015 12:50 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$65.33
Change (%) Stock is Down 0.98 (1.48%)
Volume2,064,699
Data as of 04/17/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
DateTitle 
04/10/15Isis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., April 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 in New York, NY; 40th Annual Deutsche Bank Health Care Conference on Thursday, May 7, 2015 in Boston, MA; 2015 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 12, 201... 
Printer Friendly Version
03/23/15Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx
CARLSBAD, Calif., March 23, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx.  In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).  In addition, statistically significant reductions from baseline in lipid parameters w... 
Printer Friendly Version
03/06/15Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
CARLSBAD, Calif., March 6, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $9 million milestone payment from Biogen Idec related to advancing the ongoing pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA).  ENDEAR, a Phase 3 study of ISIS-SMNRx, is a randomized, double-blind, sham-procedure controlled thirteen month study in approximately 110 infants diagnosed with SMA.  The study will evaluate the e... 
Printer Friendly Version
03/02/15Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., March 2, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  "We are very pleased with the progress we are making with ISIS-TTRRx, and plan to report data from the Phase 2/3 study in 2017.  We have many patients who have completed the fifteen months of dosing and are now recei... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
04/15/15
through
04/18/15
67th AAN Annual Meeting
LocationWashington, DC
04/18/15
through
04/22/15
AACR Annual Meeting 2015
LocationPhiladelphia, PA
04/19/15
through
04/24/15
Keystone Conference: The Crossroads of Lipid Metabolism and Diabetes
LocationCopenhagen, Denmark
05/03/15
through
05/06/15
TIDES 2015
LocationSan Diego, CA
05/03/15
through
05/07/15
ARVO 2015
LocationDenver, CO
05/07/15 12:50 p.m. ET
40th Annual Deutsche Bank Health Care Conference
LocationBoston, MA
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up